Gut Microbiome Profiling in Patients With Chronic Heart Failure
Launched by STANFORD UNIVERSITY · Apr 10, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
During this study, investigators will recruit adults diagnosed with chronic heart failure with reduced ejection fraction caused by non-ischemic cardiomyopathy. These individuals will undergo longitudinal profiling. This will include detailed profiling of their (1) gut microbiome, (2) blood metabolic and immune markers, and (3) heart failure clinical status. Integrated results will lead to deeper understanding of how gut microbiome interacts with and affects the host in chronic heart failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Heart failure with reduced ejection fraction (left ventricular ejection fraction less than 50%)
- • Non-ischemic cardiomyopathy
- • Body mass index (BMI) 18-40 kg/m2
- Exclusion Criteria:
- • Treated diabetes
- • Advanced kidney disease
- • Cirrhosis
- • Significant gastrointestinal disease including any history of inflammatory bowel disease
- • History of extensive bowel resection
- • Active malignancy or systemic chemotherapy within the past 12 months
- • Active infection
- • Current or recent (within 4 weeks) use of systemic antibiotics, commercial probiotics, immunosuppressive or immunomodulatory medications
- • Pregnancy/lactation
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported